Literature DB >> 11832309

Rationale and assessment of minimally invasive approaches to benign prostatic hyperplasia therapy.

Thayne R Larson1.   

Abstract

Benign prostatic hyperplasia affects quality of life, with most patients complaining of symptoms related to urination. For this reason, successful treatments can be defined by (1) their effect on lower urinary tract symptoms, (2) their impact on quality of life, and (3) their ability to unobstruct the flow of urine through the prostate. Minimally invasive therapy (MIT), which includes transurethral microwave thermotherapy, water-induced thermotherapy, interstitial devices (eg, transurethral needle ablation), and interstitial laser treatments, offers physicians and their patients cost-effective alternatives for achieving a substantially improved quality of life at an acceptable level of risk. Evidence-based medicine indicates that MIT is safe and achieves significant symptomatic improvement. Compared with long-term medical management, minimally invasive procedures offer effective, well-tolerated 1-time intervention with lasting effects that can be achieved on an outpatient basis. This article reviews the options for MIT.

Entities:  

Mesh:

Year:  2002        PMID: 11832309     DOI: 10.1016/s0090-4295(01)01557-6

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  11 in total

1.  Economic impact of surgical intervention in the treatment of benign prostatic hyperplasia.

Authors:  John M Hollingsworth; John T Wei
Journal:  Rev Urol       Date:  2006

2.  Efficacy and safety of prostate vaporesection using a 120-W 2-μm continuous-wave Tm:YAG laser (RevoLix 2) in patients on continuous oral anticoagulant or antiplatelet therapy.

Authors:  Luciano Macchione; Giuseppe Mucciardi; Alessandro Gali'; Antonina Di Benedetto; Salvatore Butticè; Carlo Magno
Journal:  Int Urol Nephrol       Date:  2013-07-27       Impact factor: 2.370

3.  Transurethral ethanol ablation of the prostate (TEAP): an effective minimally invasive treatment alternative to traditional surgery for symptomatic benign prostatic hyperplasia (BPH) in high-risk comorbidity patients.

Authors:  Carlo Magno; Giuseppe Mucciardi; Alessandro Galì; Giuseppina Anastasi; Antonino Inferrera; Giuseppe Morgia
Journal:  Int Urol Nephrol       Date:  2008-05-14       Impact factor: 2.370

4.  The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States.

Authors:  David A Taub; John T Wei
Journal:  Curr Urol Rep       Date:  2006-07       Impact factor: 3.092

Review 5.  First-line treatment for symptomatic benign prostatic hyperplasia: is there a particular patient profile for a particular treatment?

Authors:  Ricardo R Gonzalez; Steven A Kaplan
Journal:  World J Urol       Date:  2006-05-19       Impact factor: 4.226

6.  Transurethral ultrasound applicators with dynamic multi-sector control for prostate thermal therapy: in vivo evaluation under MR guidance.

Authors:  Adam M Kinsey; Chris J Diederich; Viola Rieke; William H Nau; Kim Butts Pauly; Donna Bouley; Graham Sommer
Journal:  Med Phys       Date:  2008-05       Impact factor: 4.071

7.  Transurethral resection of the prostate with a bipolar tissue management system compared to conventional monopolar resectoscope: one-year outcome.

Authors:  Chang-Jun Yoon; Ji-Yoon Kim; Ki-Hak Moon; Hee-Chang Jung; Tong-Choon Park
Journal:  Yonsei Med J       Date:  2006-10-31       Impact factor: 2.759

Review 8.  Transurethral hot water balloon thermotherapy for benign prostatic hyperplasia.

Authors:  Lance A Mynderse; Thayne R Larson
Journal:  Curr Urol Rep       Date:  2003-08       Impact factor: 2.862

Review 9.  How do transurethral needle ablation of the prostate and transurethral microwave thermotherapy compare with transurethral prostatectomy?

Authors:  Ricardo R Gonzalez; Alexis E Te
Journal:  Curr Urol Rep       Date:  2003-08       Impact factor: 2.862

10.  Benign prostatic hyperplasia: An overview of existing treatment.

Authors:  Neelima Dhingra; Deepak Bhagwat
Journal:  Indian J Pharmacol       Date:  2011-02       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.